Sanity Group
Medical cannabis company developing cannabinoid products and therapy support for physicians and patients in Germany and Europe
Highlights
- Hiring14 open roles
- New on EvolcAdded 2026-10-28
About Sanity Group
Sanity Group GmbH is a medical cannabis company whose stated goal is unlocking the health benefits of cannabinoids. It develops cannabinoid products and draws on a Medical Advisory Board of specialists in pain therapy, palliative medicine, neurology and pharmacology.
Its work is aimed at physicians and patients in medical cannabis therapy. The company also engages in policy work on evidence-based cannabis regulation in Germany and publishes commentary on the German Cannabis Act.
In April 2026 Organigram Global, a Canadian licensed cannabis producer, announced the closing of its acquisition of Sanity Group, and Sanity founder Finn Hänsel was later appointed Chief Strategy Officer and President, Rest of World at Organigram. The combined supply and commercial network is set to span Canada, Germany, Switzerland, Poland, Czechia, the United Kingdom and Australia. The company lists 17 open roles, including pharmaceutical sales for pain therapy, a physician for medical cannabis therapy in Poland, and marketing, finance and quality control positions.
Product: Cannabinoid-based products and medical cannabis therapy support for physicians and patients.
Jobs at Sanity Group (14)
Sanity Group is hiring for 14 roles, mostly in marketing, based in Berlin.
Working Student Sales (F/M/D)
New on EvolcCustomer Care Admin (F/D/M)
New on EvolcTalent Acquisition Manager (F/D/M)
New on Evolc(Junior) Marketing Manager - Trade & POS (F/M/D)
New on EvolcFounders Associate (F/M/D)
New on EvolcQuality Control Manager (F/M/D)
New on EvolcCRM Manager (F/M/D)
New on EvolcMarketing Manager - Medical Clinics (F/M/D)
New on Evolc
Companies hiring like Sanity Group
Leadership
- Fabian Friede · ADVISOR & FOUNDERSource: company website
- Finn Hänsel · MANAGING DIRECTOR & FOUNDERSource: company website
More biotech & pharma companies
Semdor Pharma Group
Narcotics and medical cannabis pharma group supplying wholesalers, pharmacies and clinics across EuropeRemote-friendlysynergy-munich.de
Interdisciplinary research cluster investigating mechanisms behind complex neurological diseasesNew on EvolcVERTANICAL
Biopharma developing VER-01, a cannabinoid-based drug for chronic pain, with clinical programmes in Germany and the USRemote-friendlyVivalyx
Develops a blood-free organ preservation solution for transplantationNew on EvolcRemote-friendlyArevipharma
CGMP pharmaceutical ingredients and contract manufacturing for global pharmaceutical companiesNew on EvolcAvextra Pharma
Develops and manufactures cannabis-based medicines for patients and healthcare professionalsRemote-friendly
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Tag ManagerMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Content management
- ElementorHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- WPFormsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Marketing & advertising
- KlaviyoHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Privacy & consent
- UsercentricsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
